Effects of fasudil on pulmonary hypertension in clinical practice - Zhang, Yiqing; Wu, Shangjie (Pulmonary pharmacology & therapeutics, 2017)
Keywords: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - administration & dosage; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - adverse effects; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - analogs & derivatives; 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - pharmacology; Animals; Disease Models, Animal; Drug Synergism; Fasudil; Humans; Hypertension, Pulmonary - drug therapy; Hypertension, Pulmonary - physiopathology; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - pharmacology; Pulmonary arterial hypertension; Pulmonary hypertension; rho-Associated Kinases - antagonists & inhibitors; Rho-kinase; PVR/SVR; ROCK; SAP; RHC; PVR; SVR; SaO2; TPR; Pulmonary arterial hypertension; PASMC; SvO2; CI; Rho-kinase; CO; IPAH; Pulmonary hypertension; Fasudil; ET; CTD; ERA; PAH; PH; CTEPH; Qp/Qs; PDEI; 6MWD; CHD; PAP; MCT